Publications by authors named "J A Mauri-Llerda"
Objective: To determine whether patients with drug-resistant mesial temporal lobe epilepsy present with an alteration in the autonomic circadian regulation of blood pressure.
Methods: A prospective case‒control study was designed, with a case group comprising patients with drug-resistant mesial temporal lobe epilepsy and a control group comprising healthy volunteers. Twenty-four-hour outpatient blood pressure monitoring was performed to assess the existence of a normal (dipping) or altered (non-dipping) circadian pattern.
Introduction: Epilepsy is most frequent in children and elderly people. Today's population is ageing and epilepsy prevalence is increasing. The type of epilepsy and its management change with age.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to explore how self-reported sleep quality affects cognitive function, anxiety, depression, and quality of life in patients with epilepsy (PWE) receiving anti-seizure medications.
- Researchers included a sample of 150 patients, who completed various assessments, revealing that 44.4% experienced poor sleep quality and many showed signs of mild cognitive impairment.
- While sleep quality didn't independently predict cognitive issues, poor sleep was linked to increased anxiety, depression, and lower quality of life in these patients.
Aim: To analyse the care of patients with epilepsy (PwE) who visit the hospital emergency department (ED) due to an epileptic seizure.
Materials And Methods: Single-centre retrospective observational study, based on the clinical history of the PwE seen in the ED for epileptic seizures between January 2016 and December 2018. Demographic, clinical and ED management variables were collected.
Objective: To assess the effectiveness and tolerability of perampanel (PER) monotherapy in routine clinical practice for the treatment of focal onset and generalized tonic-clonic seizures (GTCS).
Methods: This multicenter, retrospective, observational study was conducted in patients aged ≥12 years treated with PER as primary monotherapy or converted to PER monotherapy by progressive reduction of background antiepileptic drugs. Outcomes included retention, responder, and seizure-free rate after 3, 6, and 12 months and tolerability throughout the follow-up.